Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare subtype of non-Hodgkin lymphoma that frequently presents with multiorgan involvement. We report a diagnostically challenging ...

How Does Zynlonta Work for B-Cell Lymphoma? Zynlonta is an antibody drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs work as smart bombs to find cancer cells in the body that ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

What Is Marginal Zone Lymphoma? Marginal zone lymphoma (MZL) isn’t one disease, but a group of rare, slow-growing blood cancers. They’re known as non-Hodgkin lymphomas because they start in your ...

New research challenges the status quo that cancer treatments are responsible for accelerating the aging process, indicating that cancer itself also plays a role. A team of researchers from Moffitt ...

CAR-T cell therapy helps some with intractable lymphoma, but those who relapse have few options. Modifying the therapy's molecular target improved response. CAR-T cell therapy, which targets a ...

Hodgkin lymphoma (formerly known as Hodgkin disease), which involves an abnormal type of lymphocyte called Reed-Sternberg cells Non-Hodgkin lymphoma, which does not contain Reed-Sternberg cells Both ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

A naturally occurring byproduct of liver metabolism—the ketone body, β-hydroxybutyrate (BHB)—can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 ...